Ferumoxytol (Rienso®)

Assessment Status Assessment process complete
Drug Ferumoxytol
Brand Rienso®
Indication For the treatment of iron deficiency anaemia in adult patients with chronic kidney disease (CKD). 
Assessment Process
Full pharmacoeconomic assessment commissioned by HSE 12/08/2012
NCPE assessment completed 17/08/2012
NCPE assessment outcome Full pharmacoeconomic evaluation not recommended.

Fluticasone furoate/vilanterol (Relvar™ Ellipta™)

Assessment Status Rapid Review Complete
Drug Fluticasone furoate/vilanterol
Brand Relvar™ Ellipta™
Indication For both (i) the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta-2-agonist. and (ii) for symptomatic treatment of patients with COPD with a FEV1<70% of predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy.
Assessment Process
Rapid review commissioned 10/12/2013
Rapid review completed 23/12/2013
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.

Meningitis B Vaccine – February 2014

Meningitis B Vaccine – February 2014

Economic Evaluation of a Universal Meningitis B Vaccination Programme in Ireland

In February 2014, the National Centre for Pharmacoeconomics completed the evaluation of the cost-effectiveness of a universal rotavirus vaccination programme in Ireland, on behalf of the National Immunisation Advisory Committee (NIAC). A summary of the main findings are available in the attached document.

Summary February 2014

Pre-submission meetings

Pre-Submission Meetings

The NCPE hosts pre-submission meetings with Applicants once the Corporate Pharmaceutical Unit has stated that a Health Technology Assessment (HTA) is required to inform a drug reimbursement decision.

What is the purpose of a pre-submission meeting?

The pre-submission meeting provides an opportunity for the Applicant to meet with the NCPE Review Team prior to finalising their HTA submission. The purpose is to outline the proposed approach to the clinical and cost-effectiveness modelling, and to obtain guidance from the NCPE on what may be the most appropriate approaches to adopt. The aim is to help the Applicant provide the best quality HTA submission possible, in order to avoid challenges later in the assessment process.

The NCPE Pre-Submission Meeting Guidance for Applicants contains all of the information to help Applicant’s plan the pre-submission meeting. Please click on the link below to download a copy.

NCPE Pre-submission Guidance for Applicant

TCD/NCPE Course on Evidence Synthesis

TCD/NCPE Course on Evidence Synthesis – 9th/ 10th September 2013

Trinity College Dublin in collaboration with the NCPE will run a 2 day course on evidence synthesis for health technology assessments (HTAs).  The course will provide an introduction to Bayesian analysis using WinBUGs, as applied to evidence synthesis for health economic evaluations.  The emphasis will be on practical examples of meta-analyses and mixed treatment comparisons. Code and software to carry out the analyses will be provided.  Prior knowledge of WinBUGs will not be necessary. To book a place on this course please contact  [email protected]

Course leaders: Professor Cathal Walsh and Dr. Susanne Schmitz

Cost: €500 for two days


R Project Training Course*   1st/2nd July 2013



A full-time temporary position for a Research Information Specialist.

All relevant information is available from the St James’s Hospital website. Closing date is 19th December 2019.

Enquiries regarding the position can be made to Dr. Lesley Tilson, Chief I Pharmacist (Tel:01 410 3427. Email: [email protected]) or Prof. Michael Barry, Clinical Director (Tel: 01 416 2191. Email: [email protected]).